PMID- 21368772 OWN - NLM STAT- MEDLINE DCOM- 20120127 LR - 20211020 IS - 1476-5470 (Electronic) IS - 1466-4879 (Print) IS - 1466-4879 (Linking) VI - 12 IP - 6 DP - 2011 Sep TI - The role of HLA-DR-DQ haplotypes in variable antibody responses to anthrax vaccine adsorbed. PG - 457-65 LID - 10.1038/gene.2011.15 [doi] AB - Host genetic variation, particularly within the human leukocyte antigen (HLA) loci, reportedly mediates heterogeneity in immune response to certain vaccines; however, no large study of genetic determinants of anthrax vaccine response has been described. We searched for associations between the immunoglobulin G antibody to protective antigen (AbPA) response to Anthrax Vaccine Adsorbed (AVA) in humans, and polymorphisms at HLA class I (HLA-A, -B, and -C) and class II (HLA-DRB1, -DQA1, -DQB1, -DPB1) loci. The study included 794 European-Americans and 200 African-Americans participating in a 43-month, double-blind and placebo-controlled clinical trial of AVA (clinicaltrials.gov identifier NCT00119067). Among European-Americans, genes from tightly linked HLA-DRB1, -DQA1, -DQB1 haplotypes displayed significant overall associations with longitudinal variation in AbPA levels at 4, 8, 26 and 30 weeks from baseline in response to vaccination with three or four doses of AVA (global P=6.53 x 10(-4)). In particular, carriage of the DRB1-DQA1-DQB1 haplotypes (*)1501-(*)0102-(*)0602 (P=1.17 x 10(-5)), (*)0101-(*)0101-(*)0501 (P=0.009) and (*)0102-(*)0101-(*)0501 (P=0.006) was associated with significantly lower AbPA levels. In carriers of two copies of these haplotypes, lower AbPA levels persisted following subsequent vaccinations. No significant associations were observed amongst African-Americans or for any HLA class I allele/haplotype. Further studies will be required to replicate these findings and to explore the role of host genetic variation outside of the HLA region. FAU - Pajewski, N M AU - Pajewski NM AD - Section on Statistical Genetics, University of Alabama at Birmingham, Birmingham, AL 35294-0022, USA. FAU - Parker, S D AU - Parker SD FAU - Poland, G A AU - Poland GA FAU - Ovsyannikova, I G AU - Ovsyannikova IG FAU - Song, W AU - Song W FAU - Zhang, K AU - Zhang K FAU - McKinney, B A AU - McKinney BA FAU - Pankratz, V S AU - Pankratz VS FAU - Edberg, J C AU - Edberg JC FAU - Kimberly, R P AU - Kimberly RP FAU - Jacobson, R M AU - Jacobson RM FAU - Tang, J AU - Tang J FAU - Kaslow, R A AU - Kaslow RA LA - eng SI - ClinicalTrials.gov/NCT00119067 GR - N01 AI040068/AI/NIAID NIH HHS/United States GR - N01AI40068/AI/NIAID NIH HHS/United States GR - T32 HL072757/HL/NHLBI NIH HHS/United States GR - T32 HL072757-09/HL/NHLBI NIH HHS/United States PT - Clinical Trial PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, P.H.S. DEP - 20110303 PL - England TA - Genes Immun JT - Genes and immunity JID - 100953417 RN - 0 (Anthrax Vaccines) RN - 0 (HLA-DQ Antigens) RN - 0 (HLA-DR Antigens) RN - 0 (Histocompatibility Antigens Class I) RN - 0 (Immunoglobulin G) SB - IM MH - Adult MH - Aged MH - Alleles MH - Anthrax/immunology MH - Anthrax Vaccines/*immunology MH - Antibody Formation/*genetics MH - Female MH - Gene Frequency MH - Genetic Variation MH - Genotype MH - HLA-DQ Antigens/*genetics MH - HLA-DR Antigens/*genetics MH - Haplotypes MH - Histocompatibility Antigens Class I/genetics MH - Humans MH - Immunoglobulin G/biosynthesis/genetics MH - Male MH - Middle Aged MH - Polymorphism, Single Nucleotide PMC - PMC3165112 MID - NIHMS297849 EDAT- 2011/03/04 06:00 MHDA- 2012/01/28 06:00 PMCR- 2012/03/01 CRDT- 2011/03/04 06:00 PHST- 2011/03/04 06:00 [entrez] PHST- 2011/03/04 06:00 [pubmed] PHST- 2012/01/28 06:00 [medline] PHST- 2012/03/01 00:00 [pmc-release] AID - gene201115 [pii] AID - 10.1038/gene.2011.15 [doi] PST - ppublish SO - Genes Immun. 2011 Sep;12(6):457-65. doi: 10.1038/gene.2011.15. Epub 2011 Mar 3.